Chinese expert consensus statement on the clinical application of AFP/AFP‐L3%/DCP using GALAD and GALAD‐like algorithm in HCC

• Published in: Journal of clinical laboratory analysis Vol. 37; no. 23-24; pp. e24990 - n/a
• Main Authors: Huang, Chenjun, Xiao, Xiao, Zhou, Lin, Chen, Fuxiang, Wang, Jianyi, Hu, Xiaobo, Gao, Chunfang, Chen, Jie, Duan, Yong, Duan, Zhaohui, Fang, Meng, Gao, Zhiyuan, Gu, Bing, Guo, Lin, Hu, Bo, Huang, Tao, Ji, Jun, Jia, Jianan, Jiang, Yanfang, Ju, Shaoqing, Ju, Yi, Lin, Jinbiao, Lin, Yong, Liu, Jiayun, Liu, Jie, Liu, Lijuan, Liu, Xinghui, Lou, Jiatao, Lou, Jinli, Lu, Qun, Lu, Renquan, Lu, Zhiming, Qiu, Zhiquan, Ren, Li, Sheng, Huiming, Su, Haixiang, Tao, Zhihua, Wang, Junjun, Wang, Ying, Wu, Wenjuan, Yang, Ximing, Yang, Zaixing, Yu, Zhuo, Yuan, Xiaopeng, Zhang, Rui, Zhang, Tao, Zhou, Qiang, Zhu, Junfeng, Zhu, Yuqing, Zhu, Zhaoqin
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.12.2023; John Wiley and Sons Inc
• Subjects: Algorithms; alpha‐fetoprotein (AFP); alpha‐fetoprotein‐L3% (AFP‐L3%); Biomarkers; Cancer therapies; Cholangiocarcinoma; Clinical medicine; Clinical practice guidelines; Consensus; des‐gamma‐carboxyprothrombin (DCP); Diagnosis; Family medical history; gender‐age‐AFP‐L3%‐AFP‐DCP (GALAD) model; Hepatitis B; Hepatocellular carcinoma; hepatocellular carcinoma (HCC); Liver cancer; Liver cirrhosis; Liver diseases; Malignancy; Medical diagnosis; Medical screening; Mortality; Surveillance; Tumors; Ultrasonic imaging; Viral infections; China; gender-age-AFP-L3%-AFP-DCP (GALAD) model; hepatocellular carcinoma (HCC); alpha-fetoprotein (AFP); des-gamma-carboxyprothrombin (DCP); alpha-fetoprotein-L3% (AFP-L3%)
• ISSN: 0887-8013; 1098-2825; 1098-2825
• DOI: 10.1002/jcla.24990

Background Primary hepatocellular carcinoma (HCC) is one of the most prevalent world‐wide malignancies. Half of the newly developed HCC occurs in China. Optimizing the strategies for high‐risk surveillance and early diagnosis are pivotal for improving 5‐year survival. Constructing the scientific non‐invasive detection technologies feasible for medical and healthcare institutions is among the key routes for elevating the efficacies of HCC identification and follow‐up. Results Based on the Chinese and international guidelines, expert consensus statements, literatures and evidence‐based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple‐biomarker (AFP, AFP‐L3%, DCP) based GALAD, GALAD like models for liver cancer. Conclusions The compile of this consensus statement aims to address and push the reasonable application of the triple‐biomarker (AFP, AFP‐L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.